Scientech Research LLC Takes $896,000 Position in Natera, Inc. $NTRA

Scientech Research LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,338 shares of the medical research company's stock, valued at approximately $896,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LRI Investments LLC acquired a new position in shares of Natera in the 4th quarter valued at $29,000. Bank of Jackson Hole Trust acquired a new stake in Natera in the first quarter valued at about $29,000. Rakuten Securities Inc. lifted its stake in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after purchasing an additional 119 shares during the period. TCTC Holdings LLC boosted its position in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Finally, ORG Partners LLC acquired a new stake in shares of Natera in the first quarter valued at approximately $32,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research analyst reports. Morgan Stanley reissued an "overweight" rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Stephens reiterated an "overweight" rating and set a $183.00 target price on shares of Natera in a report on Friday, August 15th. Barclays reiterated an "overweight" rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Piper Sandler reiterated an "overweight" rating and set a $220.00 target price (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price target for the company in a research note on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to data from MarketBeat, Natera presently has an average rating of "Buy" and an average target price of $194.00.

Insider Buying and Selling at Natera

In related news, insider John Fesko sold 678 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88. Following the completion of the transaction, the insider owned 152,747 shares in the company, valued at $23,746,048.62. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $166.62, for a total transaction of $499,860.00. Following the transaction, the insider directly owned 120,859 shares of the company's stock, valued at $20,137,526.58. This represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock valued at $8,459,656 over the last quarter. Company insiders own 5.63% of the company's stock.

Natera Price Performance

Shares of NTRA stock traded down $3.84 on Friday, hitting $169.97. The company's stock had a trading volume of 547,614 shares, compared to its average volume of 1,467,510. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $183.00. The firm's fifty day moving average price is $155.04 and its 200-day moving average price is $154.09. The stock has a market capitalization of $23.33 billion, a price-to-earnings ratio of -88.80 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the previous year, the company earned ($0.30) EPS. The firm's revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.